NAP: Training (2007)
Citation:
Horvath PJ, Eagen CK, Fisher NM, Leddy JJ, Pendergast DR. The effects of varying dietary fat on performance and metabolism in trained male and female runners. J Am Coll Nutr. 2000; 19 (1): 52-60.
PubMed ID: 10682876Study Design:
Non-Controlled Trial
Class:
D - Click here for explanation of classification scheme.
Quality Rating:

Research Purpose:
To determine if increasing dietary fat intake from the low levels (about 15% of daily calories) typical of runners to higher levels (about 45% of daily calories), while maintaining adequate levels of carbohydrates, increased VO2max and endurance time, as well as to investigate the potential mechanisms involved.
Inclusion Criteria:
Runners running a minimum of 35 miles per week, healthy, non-smoking, between ages of 18 and 55 years.
Exclusion Criteria:
Excluded if not included above.
Description of Study Protocol:
- Recruitment: 1,300 runners from the greater Buffalo metropolitan area running community were sent letters requesting their participation in the study.
- Design: Non-randomized clinical trial
- Blinding used: Not used.
- Intervention: Subjects consumed diets of 16%, 31% or 44% fat for four weeks.
Statistical Analysis
- Comparisons were made using all 25 subjects between the first two diets and using 12 subjects between the last two diets
- Two-way ANOVA with repeated measures was used with diet and gender as the main factors for all performance data
- For blood measurements, a three-way ANOVA with repeated measures was done using diet, gender and time during the exercise test as the main factors
- The effects of low- to medium-fat diets were analyzed with N=25 and the medium- to high-fat diets analyzed with N=12
- Post-hoc testing to determine significant difference among the means was done using the Newman-Kuels post-hoc test (P<0.05).
Data Collection Summary:
Timing of Measurements
- Endurance and VO2max tested at the end of each diet
- Blood sampled before and after the VO2max and endurance runs.
Dependent Variables
- Endurance; run to exhaustion at 80% of VO2max
- Wingate Anaerobic Power Test
- VO2max measured through expired gas collection
- Plasma levels of lactate, pyruvate, glucose, glycerol and triglycerides measured by colorimetric commercial kits
- Free fatty acids assayed using spectrophotometric method
- Body weight measured on electronic scale
- Body fat percentage measured by underwater densitometry.
Independent Variables
- Isocaloric diets of 16%, 31% or 44% fat for four weeks
- Given one-week sample menus to follow, but food was self-selected
- Subjects taught how to record their food, fluid and supplement intake and returned food records weekly to dietitians for review to determine compliance
- No washout period.
Description of Actual Data Sample:
- Initial N: 45 subjects originally met the criteria to participate, but it is unclear how many enrolled.
- Attrition (final N): 25 subjects completed the study; 12 males and 13 females completed the first two diet periods and six males and six females completed all three diet periods
Age
- Females: 33±2.2 years for LF-MF, 32±3.2 for MF-HF
- Males: 37±2.0 for LF-MF, 36±2.6 for MF-HF.
Ethnicity
Not mentioned.
Anthropometrics
Males and females were significantly different from each other in terms of height, weight, body fat and VO2max.
Location
Buffalo, New York.
Summary of Results:
Measurements During the Endurance Run
Time (Minutes) | Maximum Heart Rate (BPM) | R | |
Female; 16% fat |
39.23±11.23
|
162.5±2.6
|
0.94±0.01
|
Female; 31% fat |
46.61±13.46
|
163.7±2.5 |
0.96±0.01 |
Male; 16% fat |
44.32±9.55
|
164.4±2.7
|
0.96±0.01
|
Male; 31% fat |
54.94±12.84
|
159.7±2.8
|
0.97±0.01
|
Female; 33% fat |
47.22±11.64
|
160.5±4.3
|
0.96±0.01
|
Female; 44% fat |
48.17±15.28
|
164.8±4.2
|
0.96±0.01
|
Male; 33% fat |
47.08±10.07
|
160.0±3.4
|
0.97±0.02
|
Male; 44% fat |
48.49±11.64
|
160.0±2.4 |
0.95±0.02 |
Other Findings
- Runners on the low-fat diet ate 19% fewer calories than on the medium- or high-fat diets
- Fat levels actually consumed by runners were 16% and 31% for 25 subjects used on low- to medium-fat diet comparisons and 33% and 44% for 12 subjects used for medium- and high-fat comparisons
- Body weight, body fat percentage, VO2max and anaerobic power were not affected by the level of dietary fat
- Endurance time increased from the low-fat to medium-fat diet by 14% (increased 20% in females and 8% in males). There were no significant differences between the high- and medium-fat diets.
- No differences were seen in plasma lactate, glucose, glycerol, triglycerides and fatty acids, when comparing the low- vs. the medium-fat diet
- Subjects who increased dietary fat to 44% had higher plasma pyruvate (46%) and lower lactate levels (39%) after the endurance run.
Author Conclusion:
- These data support previous studies demonstrating that increased dietary fat intake, without compromising carbohydrate intake, improves endurance performance
- If the diet is hypocaloric however, increasing fat and decreasing carbohydrates reduces glycogen stores and impairs performance
- Clearly demonstrated by the reduced running capacity on the low-fat diet, reduction in total calories or fat is not conducive to optimal exercise performance
- It is suggested that the intramuscular stores of glycogen and fats are the crucial ones as the rate of supply from the blood is too slow to meet energy requirements
- The blood substrates are important for the replenishment of intramuscular stores during recovery from exercise
- The present study extends these observations to female runners and runners of a more recreational nature
- The present study does not support the hypothesis that increasing fat to 44% of total calories improves performance to a greater extent than does 31% fat. However, further studies using more intensely trained athletes with lower body fat are needed.
Funding Source:
Industry: |
|
Reviewer Comments:
- Compliance assessed by dietitian review, but subjects did not follow diets well and only half of subjects increased fat intake to 44%
- Unclear as to how many of 45 subjects asked to participate actually enrolled
- No washout period between diets.
Quality Criteria Checklist: Primary Research
|
|||
Relevance Questions | |||
1. | Would implementing the studied intervention or procedure (if found successful) result in improved outcomes for the patients/clients/population group? (Not Applicable for some epidemiological studies) | Yes | |
2. | Did the authors study an outcome (dependent variable) or topic that the patients/clients/population group would care about? | Yes | |
3. | Is the focus of the intervention or procedure (independent variable) or topic of study a common issue of concern to dieteticspractice? | Yes | |
4. | Is the intervention or procedure feasible? (NA for some epidemiological studies) | Yes | |
Validity Questions | |||
1. | Was the research question clearly stated? | Yes | |
1.1. | Was (were) the specific intervention(s) or procedure(s) [independent variable(s)] identified? | Yes | |
1.2. | Was (were) the outcome(s) [dependent variable(s)] clearly indicated? | Yes | |
1.3. | Were the target population and setting specified? | Yes | |
2. | Was the selection of study subjects/patients free from bias? | ??? | |
2.1. | Were inclusion/exclusion criteria specified (e.g., risk, point in disease progression, diagnostic or prognosis criteria), and with sufficient detail and without omitting criteria critical to the study? | Yes | |
2.2. | Were criteria applied equally to all study groups? | ??? | |
2.3. | Were health, demographics, and other characteristics of subjects described? | Yes | |
2.4. | Were the subjects/patients a representative sample of the relevant population? | ??? | |
3. | Were study groups comparable? | N/A | |
3.1. | Was the method of assigning subjects/patients to groups described and unbiased? (Method of randomization identified if RCT) | N/A | |
3.2. | Were distribution of disease status, prognostic factors, and other factors (e.g., demographics) similar across study groups at baseline? | N/A | |
3.3. | Were concurrent controls or comparisons used? (Concurrent preferred over historical control or comparison groups.) | N/A | |
3.4. | If cohort study or cross-sectional study, were groups comparable on important confounding factors and/or were preexisting differences accounted for by using appropriate adjustments in statistical analysis? | N/A | |
3.5. | If case control study, were potential confounding factors comparable for cases and controls? (If case series or trial with subjects serving as own control, this criterion is not applicable.) | N/A | |
3.6. | If diagnostic test, was there an independent blind comparison with an appropriate reference standard (e.g., "gold standard")? | N/A | |
4. | Was method of handling withdrawals described? | ??? | |
4.1. | Were follow-up methods described and the same for all groups? | ??? | |
4.2. | Was the number, characteristics of withdrawals (i.e., dropouts, lost to follow up, attrition rate) and/or response rate (cross-sectional studies) described for each group? (Follow up goal for a strong study is 80%.) | ??? | |
4.3. | Were all enrolled subjects/patients (in the original sample) accounted for? | ??? | |
4.4. | Were reasons for withdrawals similar across groups? | ??? | |
4.5. | If diagnostic test, was decision to perform reference test not dependent on results of test under study? | N/A | |
5. | Was blinding used to prevent introduction of bias? | No | |
5.1. | In intervention study, were subjects, clinicians/practitioners, and investigators blinded to treatment group, as appropriate? | No | |
5.2. | Were data collectors blinded for outcomes assessment? (If outcome is measured using an objective test, such as a lab value, this criterion is assumed to be met.) | No | |
5.3. | In cohort study or cross-sectional study, were measurements of outcomes and risk factors blinded? | N/A | |
5.4. | In case control study, was case definition explicit and case ascertainment not influenced by exposure status? | N/A | |
5.5. | In diagnostic study, were test results blinded to patient history and other test results? | N/A | |
6. | Were intervention/therapeutic regimens/exposure factor or procedure and any comparison(s) described in detail? Were interveningfactors described? | ??? | |
6.1. | In RCT or other intervention trial, were protocols described for all regimens studied? | Yes | |
6.2. | In observational study, were interventions, study settings, and clinicians/provider described? | N/A | |
6.3. | Was the intensity and duration of the intervention or exposure factor sufficient to produce a meaningful effect? | Yes | |
6.4. | Was the amount of exposure and, if relevant, subject/patient compliance measured? | ??? | |
6.5. | Were co-interventions (e.g., ancillary treatments, other therapies) described? | Yes | |
6.6. | Were extra or unplanned treatments described? | Yes | |
6.7. | Was the information for 6.4, 6.5, and 6.6 assessed the same way for all groups? | Yes | |
6.8. | In diagnostic study, were details of test administration and replication sufficient? | N/A | |
7. | Were outcomes clearly defined and the measurements valid and reliable? | Yes | |
7.1. | Were primary and secondary endpoints described and relevant to the question? | Yes | |
7.2. | Were nutrition measures appropriate to question and outcomes of concern? | Yes | |
7.3. | Was the period of follow-up long enough for important outcome(s) to occur? | Yes | |
7.4. | Were the observations and measurements based on standard, valid, and reliable data collection instruments/tests/procedures? | Yes | |
7.5. | Was the measurement of effect at an appropriate level of precision? | Yes | |
7.6. | Were other factors accounted for (measured) that could affect outcomes? | Yes | |
7.7. | Were the measurements conducted consistently across groups? | Yes | |
8. | Was the statistical analysis appropriate for the study design and type of outcome indicators? | Yes | |
8.1. | Were statistical analyses adequately described and the results reported appropriately? | Yes | |
8.2. | Were correct statistical tests used and assumptions of test not violated? | Yes | |
8.3. | Were statistics reported with levels of significance and/or confidence intervals? | Yes | |
8.4. | Was "intent to treat" analysis of outcomes done (and as appropriate, was there an analysis of outcomes for those maximally exposed or a dose-response analysis)? | N/A | |
8.5. | Were adequate adjustments made for effects of confounding factors that might have affected the outcomes (e.g., multivariate analyses)? | N/A | |
8.6. | Was clinical significance as well as statistical significance reported? | Yes | |
8.7. | If negative findings, was a power calculation reported to address type 2 error? | N/A | |
9. | Are conclusions supported by results with biases and limitations taken into consideration? | Yes | |
9.1. | Is there a discussion of findings? | Yes | |
9.2. | Are biases and study limitations identified and discussed? | Yes | |
10. | Is bias due to study's funding or sponsorship unlikely? | Yes | |
10.1. | Were sources of funding and investigators' affiliations described? | Yes | |
10.2. | Was the study free from apparent conflict of interest? | Yes | |